Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 5, 2014, Pages 724-729

  Castagna, Luca ^a   Crocchiolo, Roberto ^a   Furst, Sabine ^b   Bramanti, Stefania ^a   El Cheikh, Jean ^b   Sarina, Barbara ^a   Granata, Angela ^b   Mauro, Elisa ^a   Faucher, Catherine ^b   Mohty, Bilal ^b   Harbi, Samia ^b   Chabannon, Christian ^b,c,d   Carlo Stella, Carmelo ^a   Santoro, Armando ^a   Blaise, Didier ^b,c,d  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Haploidentical transplantation; Postinfusion cyclophosphamide; Stem cell sources

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; HLA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; ALKYLATING AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE EFFECTIVENESS; CONTINUOUS INFUSION; ENGRAFTMENT; FEMALE; HAPLOIDENTICAL T LYMPHOCYTE REPLETE TRANSPLANTATION; HEMATOPOIETIC STEM CELL; HUMAN; INFECTIOUS COMPLICATION; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL COUNT; NONMYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD STEM CELL; RETROSPECTIVE STUDY; SEPSIS; THROMBOCYTE COUNT; VIREMIA; VIRUS PNEUMONIA; WHOLE BODY RADIATION; ACUTE DISEASE; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; COMPARATIVE STUDY; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TEST; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; PATHOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SURVIVAL;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW TRANSPLANTATION; CYCLOPHOSPHAMIDE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84897957070     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.02.001     Document Type: Article

References (26)

1. Anasetti C., Amos D., Beatty P.G., et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. NEngl J Med 1989, 320:197-204.
2. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. JClin Oncol 2005, 23:3447-3454.
3. Federmann B., Bornhauser M., Meisner C., et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica 2012, 97:1523-1531.
4. Ciceri F., Bonini C., Lupo Stanghellini M.T., et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009, 10:489-500.
5. Dodero A., Carniti C., Raganato A., et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen infusions for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte contribute to improve T-cell recovery. Blood 2009, 113:4771-4779.
6. Rizzieri D.A., Koh L.P., Long G.D., et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. JClin Oncol 2007, 25:690-697.
7. Lee K.-H., Lee J.-H., Lee J.-H., et al. Hematopoietic cell transplantation from an hla-mismatched familial donor is feasible without exvivo T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Biol Blood Marrow Transplant 2009, 15:61-72.
8. Huang X.J., Zhu H.H., Chang Y.J., et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 2012, 119:5584-5590.
9. Di Bartolomeo P., Santarone S., De Angelis G., et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013, 121:849-857.
10. Santos G.W., Owens A.H. Acomparison of the effects of selected cytotoxic agents on allogeneic skin graft survival in rats. Bull Johns Hopkins Hosp 1965, 116:327-340.
11. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
12. Solomon S.R., Sizemore C.A., Sanacore M., et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012, 18:1859-1866.
13. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
14. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
15. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
16. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
17. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
18. Cox D. Regression models and life tables. JR Stat Soc (B) 1972, 34:187-220.
19. Luznik L., Jones R.J., Fuchs E.J. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol 2010, 17:493-499.
20. Luznik L., Jalla S., Engstrom L.W., et al. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant 2002, 8:131-138.
21. Ottinger H.D., Beelen D.W., Scheulen B., et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996, 88:2775-2779.
22. Korbling M., Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?. Blood 2001, 98:2900-2908.
23. Storb R., Gyurkocza B., Storer B.E., et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. JClin Oncol 2013, 31:1530-1538.
24. Peggs K.S., Sureda A., Qian W., et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007, 139:70-80.
25. Crocchiolo R., Esterni B., Castagna L., et al. Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. Cancer 2013, 119:986-992.
26. Burroughs L.M., O'Donnell P.V., Sandmaier B.M., et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:1279-1287.